{"id":"NCT02367781","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","officialTitle":"A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-04-16","primaryCompletion":"2018-03-15","completion":"2021-01-18","firstPosted":"2015-02-20","resultsPosted":"2019-04-03","lastUpdate":"2021-08-09"},"enrollment":723,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Non-Squamous Non-Small Cell Lung"],"interventions":[{"type":"DRUG","name":"Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody","otherNames":["MPDL3280A, RO5541267, Tecentriq"]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Nab-Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Pemetrexed","otherNames":[]}],"arms":[{"label":"Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)","type":"EXPERIMENTAL"},{"label":"Arm B (Nab-Paclitaxel+Carboplatin)","type":"ACTIVE_COMPARATOR"}],"summary":"This randomized Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 \\[PD-L1\\] antibody) in combination with carboplatin+nab-paclitaxel compared with treatment with carboplatin+nab-paclitaxel in chemotherapy-naive participants with Stage IV non-squamous NSCLC. Participants were randomized in a 2:1 ratio to Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) or Arm B (Nab-Paclitaxel+Carboplatin).","primaryOutcome":{"measure":"Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the ITT-WT Population","timeFrame":"Up to approximately 35 months after first patient enrolled","effectByArm":[{"arm":"Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)","deltaMin":7,"sd":null},{"arm":"Arm B (Nab-Paclitaxel+Carboplatin)","deltaMin":5.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":132,"countries":["United States","Belgium","Canada","France","Germany","Israel","Italy","Spain"]},"refs":{"pmids":["36795388","35511917","31122901"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":252,"n":473},"commonTop":["ANAEMIA","NAUSEA","FATIGUE","NEUTROPENIA","DIARRHOEA"]}}